Docetaxel-Loaded Disulfide Cross-Linked Nanoparticles Derived from Thiolated Sodium Alginate for Colon Cancer Drug Delivery

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Jan 8

PMID 31906511

Citations 14

Authors

Hock Ing Chiu

Asila Dinie Ayub

Siti Nur Aishah Mat Yusuf

Noorfatimah Yahaya

Erazuliana Abbd Kadir

Vuanghao Lim

Affiliations

Soon will be listed here.

Abstract

In this study, fluorescein-labelled wheat germ agglutinin (fWGA)-conjugated disulfide cross-linked sodium alginate nanoparticles were developed to specifically target docetaxel (DTX) to colon cancer cells. Different amounts of 3-mercaptopropionic acid (MPA) were covalently attached to sodium alginate to form thiolated sodium alginate (MPA1-5). These polymers were then self-assembled and air-oxidised to form disulfide cross-linked nanoparticles (MP1-5) under sonication. DTX was successfully loaded into the resulting MP1-5 to form DTX-loaded nanoparticles (DMP1-5). DMP2 had the highest loading efficiency (17.8%), thus was chosen for fWGA surface conjugation to form fWGA-conjugated nanoparticles (fDMP2) with a conjugation efficiency of 14.1%. Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) analyses showed spherical nanoparticles, and an in vitro drug release study recorded a cumulative drug release of 48.6%. Dynamic light scattering (DLS) analysis revealed a mean diameter (MD) of 289 nm with a polydispersity index (PDI) of 0.3 and a zeta potential of -2.2 mV for fDMP2. HT-29 human colon cancer cells treated with fDMP2 showed lower viability than that of L929 mouse fibroblast cells. These results indicate that fDMP2 was efficiently taken up by HT-29 cells (29.9%). Fluorescence and confocal imaging analyses also showed possible internalisation of nanoparticles by HT-29 cells. In conclusion, fDMP2 shows promise as a DTX carrier for colon cancer drug delivery.

Citing Articles

Alginate coated mesoporous silica nanoparticles as oral delivery carrier of curcumin and quercetin to colon cancer: preparation, optimization, characterization, and anticancer activity.

Alallam B, Abdkadir E, Hayati A, Keong Y, Lim V Drug Deliv Transl Res. 2025; .

PMID: 39800814 DOI: 10.1007/s13346-024-01777-6.

Docetaxel-tethered di-Carboxylic Acid Derivatised Fullerenes: A Promising Drug Delivery Approach for Breast Cancer.

Misra C, Kaur J, Kumar M, Kaushik L, Chitkara D, Preet S AAPS PharmSciTech. 2024; 25(7):233.

PMID: 39358486 DOI: 10.1208/s12249-024-02955-y.

Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers.

Garbati P, Picco C, Magrassi R, Signorello P, Cacopardo L, Serra M Pharmaceutics. 2024; 16(3).

PMID: 38543324 PMC: 10974668. DOI: 10.3390/pharmaceutics16030431.

The Advancement and Obstacles in Improving the Stability of Nanocarriers for Precision Drug Delivery in the Field of Nanomedicine.

Mahajan K, Bhattacharya S Curr Top Med Chem. 2024; 24(8):686-721.

PMID: 38409730 DOI: 10.2174/0115680266287101240214071718.

2-Hydroxyoleic Acid as a Self-Assembly Inducer for Anti-Cancer Drug-Centered Nanoparticles.

Antoniou A, Nordio G, Di Paolo M, Colombo E, Gaffuri B, Polito L Pharmaceuticals (Basel). 2023; 16(5).

PMID: 37242505 PMC: 10220756. DOI: 10.3390/ph16050722.

References

Dodov M, Calis S, Crcarevska M, Geskovski N, Petrovska V, Goracinova K . Wheat germ agglutinin-conjugated chitosan-Ca-alginate microparticles for local colon delivery of 5-FU: development and in vitro characterization. Int J Pharm. 2009; 381(2):166-75. DOI: 10.1016/j.ijpharm.2009.06.037. View

Smitha K, Anitha A, Furuike T, Tamura H, Nair S, Jayakumar R . In vitro evaluation of paclitaxel loaded amorphous chitin nanoparticles for colon cancer drug delivery. Colloids Surf B Biointerfaces. 2013; 104:245-53. DOI: 10.1016/j.colsurfb.2012.11.031. View

Mo Y, Lim L . Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J Control Release. 2005; 107(1):30-42. DOI: 10.1016/j.jconrel.2004.06.024. View

Yun Y, Cho Y, Park K . Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev. 2012; 65(6):822-32. PMC: 3574626. DOI: 10.1016/j.addr.2012.10.007. View

Islam P, Water J, Bohr A, Rantanen J . Chitosan-Based Nano-Embedded Microparticles: Impact of Nanogel Composition on Physicochemical Properties. Pharmaceutics. 2016; 9(1). PMC: 5374367. DOI: 10.3390/pharmaceutics9010001. View

Kassem A, Farid R, Issa D, Khalil D, Abd-El-Razzak M, Saudi H . Development of mucoadhesive microbeads using thiolated sodium alginate for intrapocket delivery of resveratrol. Int J Pharm. 2015; 487(1-2):305-13. DOI: 10.1016/j.ijpharm.2015.04.010. View

Wang C, Ho P, Lim L . Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells. Int J Pharm. 2010; 400(1-2):201-10. DOI: 10.1016/j.ijpharm.2010.08.023. View

Martinez A, Olmo R, Iglesias I, Teijon J, Blanco M . Folate-targeted nanoparticles based on albumin and albumin/alginate mixtures as controlled release systems of tamoxifen: synthesis and in vitro characterization. Pharm Res. 2013; 31(1):182-93. DOI: 10.1007/s11095-013-1151-z. View

Zhang G, Qiao J, Liu X, Liu Y, Wu J, Huang L . Interactions of Self-Assembled S Polysaccharide Nanoparticles with Bovine Serum Albumin and Biodistribution of Its Docetaxel-Loaded Nanoparticles. Pharmaceutics. 2019; 11(1). PMC: 6358745. DOI: 10.3390/pharmaceutics11010043. View

10.

Mat Yusuf S, Ng Y, Ayub A, Ngalim S, Lim V . Characterisation and Evaluation of Trimesic Acid Derivatives as Disulphide Cross-Linked Polymers for Potential Colon Targeted Drug Delivery. Polymers (Basel). 2019; 9(8). PMC: 6418558. DOI: 10.3390/polym9080311. View

11.

Li H, Dong W, Zhou J, Xu X, Li F . Triggering effect of N-acetylglucosamine on retarded drug release from a lectin-anchored chitosan nanoparticles-in-microparticles system. Int J Pharm. 2013; 449(1-2):37-43. DOI: 10.1016/j.ijpharm.2013.04.008. View

12.

Savin C, Tiron C, Carasevici E, Stan C, Ibanescu S, Simionescu B . Entrapment of -Hydroxyphthalimide Carbon Dots in Different Topical Gel Formulations: New Composites with Anticancer Activity. Pharmaceutics. 2019; 11(7). PMC: 6680570. DOI: 10.3390/pharmaceutics11070303. View

13.

Dicharry R, Ye P, Saha G, Waxman E, Asandei A, Parnas R . Wheat gluten-thiolated poly(vinyl alcohol) blends with improved mechanical properties. Biomacromolecules. 2006; 7(10):2837-44. DOI: 10.1021/bm060432n. View

14.

Kim S, Lee S, Yuk D, Moon D, Choi S, Kim Y . Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch Pharm Res. 2009; 32(5):755-65. DOI: 10.1007/s12272-009-1515-4. View

15.

Conde J, Oliva N, Zhang Y, Artzi N . Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. Nat Mater. 2016; 15(10):1128-38. PMC: 6594055. DOI: 10.1038/nmat4707. View

16.

Lim V, Peh K, Sahudin S . Synthesis, characterisation, and evaluation of a cross-linked disulphide amide-anhydride-containing polymer based on cysteine for colonic drug delivery. Int J Mol Sci. 2013; 14(12):24670-91. PMC: 3876135. DOI: 10.3390/ijms141224670. View

17.

Guo X, Cheng Y, Zhao X, Luo Y, Chen J, Yuan W . Advances in redox-responsive drug delivery systems of tumor microenvironment. J Nanobiotechnology. 2018; 16(1):74. PMC: 6151045. DOI: 10.1186/s12951-018-0398-2. View

18.

Li P, Wang Y, Zeng F, Chen L, Peng Z, Kong L . Synthesis and characterization of folate conjugated chitosan and cellular uptake of its nanoparticles in HT-29 cells. Carbohydr Res. 2011; 346(6):801-6. DOI: 10.1016/j.carres.2011.01.027. View

19.

Hu Y, Xie J, Tong Y, Wang C . Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release. 2007; 118(1):7-17. DOI: 10.1016/j.jconrel.2006.11.028. View

20.

Wittaya-Areekul S, Kruenate J, Prahsarn C . Preparation and in vitro evaluation of mucoadhesive properties of alginate/chitosan microparticles containing prednisolone. Int J Pharm. 2006; 312(1-2):113-8. DOI: 10.1016/j.ijpharm.2006.01.003. View